Kramer Levin Naftalis & Frankel
Full-service law firm Kramer Levin Naftalis & Frankel was founded in 1968 and operates out of its headquarters in New York as well as from outposts in Silicon Valley and Paris. From its original practice areas of litigation, corporate, real estate, tax, and trusts and estate law, it has since grown to offer a wide assortment of legal services, including those relating to intellectual property. Its IP group has more than 45 lawyers from a variety of different technical backgrounds. The firm's legal team has litigated before both federal district and appellate courts and advises clients in the areas of prosecution, licensing, due diligence, and technology transactions.
Brian Slater, who focuses his practice specifically on complex patent litigation regarding biotechnology and pharmaceuticals. He has represented Forward Pharma in its patent interference against Biogen in the USPTO to determine patent rights to Biogen's multiple sclerosis drug, Tecfidera. Forward settled its patent dispute with Biogen for an upfront payment of $1.25 billion plus downstream royalties. Servicing a client in patent litigation, counseling and prosecution, and antitrust litigation matters, Jonathan Caplan obtained a patent infringement verdict for client Prism Technologies against Sprint Spectrum for $30 million. The technology in question related to enabling access to data services on mobile devices. Representing clients in litigation and transactions involving intellectual property rights, Vito DeBari also counsels clients regarding the evaluation of inventions for patentability, product clearance evaluations, procurement of patent rights, patent infringement and validity opinions, and licensing corporate transactions involving IP rights.
|Abelman Frayne & Schwab|
|Amster Rothstein & Ebenstein|
|Davis Wright Tremaine|
|Fish & Richardson|
|King & Spalding|
|Manatt Phelps & Phillips|
|Paul Weiss Rifkind Wharton & Garrison|